Leading therapy areas by pharma revenue in the U.S. 2023

Medications can be categorized by the type of condition they are used to treating. In 2023, revenues of anti-diabetes drugs in the United States amounted to approximately 35 billion U.S. dollars, which was only topped by anti-rheumatic and oncology drugs. High demand for drugs to treat high blood pressureIn the United States, the therapeutic class with the most prescriptions was antihypertensives, which are effective in lowering blood pressure. Sales of antihypertensives generated around 12.4 billion U.S. dollars in 2023, representing just around two percent of the total amount of money spent on medicines in the United States during the year. Counting the cost of diabetesThe number of prescriptions dispensed for the use of anti-diabetes drugs stood at 429 million in 2022; spending on anti-diabetic medicines increased over the last years. One reason for this could be a rise in the price of diabetes medications. When drug manufacturers own the patent to certain medicines, they can sell the product at a higher price because there is a lack of competition in the market. Prices start to fall when this market exclusivity ends, and generic versions enter the market.

药物可按其治疗病症的类型进行分类。截至2023年，美国抗糖尿病药物的营收约为350亿美元，仅略低于抗风湿病和肿瘤学药物。针对高血压的治疗药物需求旺盛在美国，处方量最多的治疗类别为抗高血压药，此类药物在降低血压方面效果显著。2023年抗高血压药的销售总额约为124亿美元，约占当年美国医药总支出金额的百分之二。糖尿病治疗成本的考量2022年，用于抗糖尿病药物的处方量达到4.29亿次；近年来，抗糖尿病药品的支出有所增加。这一现象的可能原因之一是糖尿病药物价格的上升。当药品制造商拥有某些药物的专利权时，由于市场缺乏竞争，他们可以以更高的价格销售产品。当市场独占权终止后，价格开始下降，市场开始出现通用版本。